Drugs / 2XP HEPTAVAX™-II
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01463683 | Nov 2011 → Nov 2012 | hepatitis B virus infection | Merck Sharp & Dohme LLC | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 2XP HEPTAVAX-II | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01463683 ↗ |
| Route | Subcutaneous | “2XP HEPTAVAX™-II vaccine 10 mcg in 0.5 mL subcutaneous injection on Day 1, Month 1, and Month 6” NCT01463683 ↗ |